Evidence Hub

Quality by Design Formulation Approach for the Development of Orodispersible Tablets of Dexlansoprazole

Ali AT, Nasir F, Hidayatullah T, Pervez S, Rabqa Zainab S, Gohar S, Ur Rahman A, Khattak MA et al.

Drug design, development and therapy, 2025

4 citations

Abstract

Purpose: Dexlansoprazole (DX) is a commercially available proton pump inhibitor (PPI). It is an oral delayed-release (DR) formulation that takes 1– 2 h to reach the systemic circulation. To overcome the delayed onset of action of conventional formulation and patient inconvenience, orodispersible tablets (ODTs) have been formulated. Drug delivery systems, especially in elderly and frequent travelers, are limited by conventional dosage forms, and ODTs are an ideal dosage form for the fast onset of action and ease of administration for these patients and are more convenient than conventional tablets for patient compliance. Methods: The formulation was optimized via Design Expert ® software (version 13.0) and evaluated for in vitro and in vivo attributes. The ODTs were compressed by the most convenient method of compression, that is, direct compression, the formulation contains a combination of citric acid and sodium bicarbonate along with Kyron T-314 ® (polymer). Pre- and post-compression evaluations were performed, and a comparative pharmacokinetic study of the DX ODT was carried out in human volunteers. Results: Drug plasma concentrations were analyzed at different time intervals through high-performance liquid chromatography (HPLC). PK Summit ® software was used to calculate various pharmacokinetic parameters. The pharmacokinetic results revealed that the T max of 0.4 h was significantly lower than that of conventional DX, indicating rapid onset of action. Stability studies…

Read the paper

Related studies

Go deeper in Evidence Hub

Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.

Open this study Sign up free